The mds Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mds Hub cannot guarantee the accuracy of translated content. The mds and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View mds content recommended for you
Guillermo Garcia-ManeroDuring the Society of Hematologic Oncology (SOHO) 2021 Annual Meeting, the MDS Hub spoke with Guillermo Garcia-Manero, MD Anderson Cancer Center, Houston, US. We asked, How have oral hypomethylating agents changed the management of MDS?
How have oral hypomethylating agents changed the management of MDS?
Garcia-Manero discusses hypomethylating agents in the management of MDS and acute myeloid leukemia (AML). He goes on to describe the challenges associated with hypomethylating agents, such as the route of administration often being intravenous/subcutaneous. Lastly, he talks about oral hypomethylating agents such as azacitidine and decitabine.